Scholarlink

Background <p>Propionic acidemia (PA) is a rare disease resulting in toxic accumulation of metabolites that cause metabolic decompensation events (MDEs). Natural history characterization of PA is limited partly due to its rarity and complexity. This study examined clinical events in participants with PA and their correlation with biomarkers to better understand the disease.</p> Methods <p>Participants diagnosed with PA (early- versus late-onset) were evaluated every 6 months from baseline to month 36. Outcome measures included annualized MDEs and changes in 3-hydroxypropionic acid (3-HP), 2-methylcitrate (2-MC), and propionylcarnitine (C3) concentrations. Blood samples were collected at each visit and during MDEs for plasma biomarker analyses. Relative risk (RR) was calculated based on MDE rates and biomarker levels.</p> Results <p>Most participants (n/<i>N</i> = 49/50, 98.0%) reported MDEs. Annualized MDE rates were highest in participants aged 0 to ≤ 1 and &gt; 1 to ≤ 2 versus &gt; 12 to ≤ 18 years (2.6 and 2.4, respectively, vs 0.2) and for early-onset versus late-onset PA (1.2 vs 0.3). A 50% decrease in plasma biomarkers was associated with a statistically significant reduction in RR of MDEs for 3-HP (RR: 0.7, 95% CI: 0.6–0.9; <i>p</i> &lt; 0.01) and a substantial reduction for C3 (RR: 0.6, 95% CI: 0.4–0.9; <i>p</i> = 0.017); no effect was observed for 2-MC.</p> Conclusions <p>MDE rates were higher in the youngest participants (0 to ≤ 2 years) versus participants aged &gt; 12 years, and with early- versus late-onset PA. Lower concentrations of 3-HP and C3 were associated with a reduced MDE risk. These findings may guide biomarker or clinical endpoints in future treatment trials.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Characterizing the frequency of clinical events and assessing biomarkers in propionic acidemia: a natural history study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月9日

查看全文
  • Bernd C. Schwahn,
  • Gerard T. Berry,
  • Hilary J. Vernon,
  • Hong Li,
  • J. Lawrence Merritt II,
  • Manuel Schiff,
  • Brigitte Chabrol,
  • Javier De las Heras,
  • Jerry Vockley,
  • Chung Lee,
  • Dwight D. Koeberl,
  • Barbara K. Burton,
  • Stephanie Grunewald,
  • George A. Diaz,
  • Can Ficicioglu,
  • Thomas Morgan,
  • Junxiang Luo,
  • Husain Attarwala,
  • Min Liang,
  • Sue Perera,
  • Vanja Sikirica

摘要

Background

Propionic acidemia (PA) is a rare disease resulting in toxic accumulation of metabolites that cause metabolic decompensation events (MDEs). Natural history characterization of PA is limited partly due to its rarity and complexity. This study examined clinical events in participants with PA and their correlation with biomarkers to better understand the disease.

Methods

Participants diagnosed with PA (early- versus late-onset) were evaluated every 6 months from baseline to month 36. Outcome measures included annualized MDEs and changes in 3-hydroxypropionic acid (3-HP), 2-methylcitrate (2-MC), and propionylcarnitine (C3) concentrations. Blood samples were collected at each visit and during MDEs for plasma biomarker analyses. Relative risk (RR) was calculated based on MDE rates and biomarker levels.

Results

Most participants (n/N = 49/50, 98.0%) reported MDEs. Annualized MDE rates were highest in participants aged 0 to ≤ 1 and > 1 to ≤ 2 versus > 12 to ≤ 18 years (2.6 and 2.4, respectively, vs 0.2) and for early-onset versus late-onset PA (1.2 vs 0.3). A 50% decrease in plasma biomarkers was associated with a statistically significant reduction in RR of MDEs for 3-HP (RR: 0.7, 95% CI: 0.6–0.9; p < 0.01) and a substantial reduction for C3 (RR: 0.6, 95% CI: 0.4–0.9; p = 0.017); no effect was observed for 2-MC.

Conclusions

MDE rates were higher in the youngest participants (0 to ≤ 2 years) versus participants aged > 12 years, and with early- versus late-onset PA. Lower concentrations of 3-HP and C3 were associated with a reduced MDE risk. These findings may guide biomarker or clinical endpoints in future treatment trials.